Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Izadora Demmer"'
Autor:
Angelina De Martin, Mechthild Lütge, Yves Stanossek, Céline Engetschwiler, Jovana Cupovic, Kirsty Brown, Izadora Demmer, Martina A. Broglie, Markus B. Geuking, Wolfram Jochum, Kathy D. McCoy, Sandro J. Stoeckli, Burkhard Ludewig
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Squamous cell carcinoma of the tonsil is one of the most frequent cancers of the oropharynx. The escalating rate of tonsil cancer during the last decades is associated with the increase of high risk-human papilloma virus (HR-HPV) infections. While th
Externí odkaz:
https://doaj.org/article/08e6db797f574e05b81a6fa907dfb228
Autor:
Luciano Wannesson, Wolfram Jochum, H. Bouchaab, David König, Wolf-Dieter Janthur, Patrizia Frösch, Martin Früh, Alex Friedlaender, Sacha I. Rothschild, Laetitia A. Mauti, Alfredo Addeo, Izadora Demmer, Sämi Schär, Sabine Schmid, Christian Britschgi, Veronika Blum
Publikováno v:
Cancer Immunology, Immunotherapy. 69:1605-1613
Early clinical trials showed promising outcomes with immune-checkpoint inhibitors (ICI) in a subset of patients with relapsed small-cell lung carcinoma (SCLC). The aim of this retrospective analysis was to assess the efficacy and safety of ICI for re
Autor:
S. Aeppli, Luciano Wannesson, Dirk Klingbiel, Miklos Pless, Martin Früh, O. Gautschi, D. Foerbs, Izadora Demmer, Sacha I. Rothschild, W.-D. Janthur, Wolfram Jochum, Christian Britschgi, Stephan Schmid
Introduction Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with antitumor activity in non-small cell lung cancer (NSCLC) with EGFR T790 M mutations. The incidence of oligo-progression (PD) on osimertinib is unknown. Methods We retrospectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed7c19aabdb410dd4594b69c62dc0d46
https://www.zora.uzh.ch/id/eprint/175172/
https://www.zora.uzh.ch/id/eprint/175172/